NO973117D0 - 1-acylpiperidinforbindelser - Google Patents

1-acylpiperidinforbindelser

Info

Publication number
NO973117D0
NO973117D0 NO973117A NO973117A NO973117D0 NO 973117 D0 NO973117 D0 NO 973117D0 NO 973117 A NO973117 A NO 973117A NO 973117 A NO973117 A NO 973117A NO 973117 D0 NO973117 D0 NO 973117D0
Authority
NO
Norway
Prior art keywords
optionally
radical
optionally substituted
alkylene
alkanoyl
Prior art date
Application number
NO973117A
Other languages
English (en)
Other versions
NO973117L (no
Inventor
Walter Schilling
Silvio Ofner
Siem Jacob Veenstra
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO973117L publication Critical patent/NO973117L/no
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO973117D0 publication Critical patent/NO973117D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO973117A 1991-08-12 1997-07-04 1-acylpiperidinforbindelser NO973117D0 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH237491 1991-08-12

Publications (2)

Publication Number Publication Date
NO973117L NO973117L (no) 1993-02-15
NO973117D0 true NO973117D0 (no) 1997-07-04

Family

ID=4232283

Family Applications (2)

Application Number Title Priority Date Filing Date
NO923123A NO303448B1 (no) 1991-08-12 1992-08-11 1-acylpiperidinforbindelser, deres anvendelse for fremstilling av legemidler samt legemidler inneholdende dem
NO973117A NO973117D0 (no) 1991-08-12 1997-07-04 1-acylpiperidinforbindelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO923123A NO303448B1 (no) 1991-08-12 1992-08-11 1-acylpiperidinforbindelser, deres anvendelse for fremstilling av legemidler samt legemidler inneholdende dem

Country Status (23)

Country Link
US (3) US5310743A (no)
EP (1) EP0532456B1 (no)
JP (1) JP3118090B2 (no)
KR (1) KR100261367B1 (no)
AT (1) ATE120456T1 (no)
AU (1) AU660180B2 (no)
CA (1) CA2075684C (no)
DE (1) DE59201771D1 (no)
DK (1) DK0532456T3 (no)
ES (1) ES2070617T3 (no)
FI (1) FI104631B (no)
GR (1) GR3015954T3 (no)
HU (1) HU221305B1 (no)
IL (2) IL102769A (no)
MX (1) MX9204627A (no)
MY (1) MY110227A (no)
NO (2) NO303448B1 (no)
NZ (1) NZ243888A (no)
PH (1) PH29963A (no)
RU (1) RU2114829C1 (no)
SA (1) SA94140632A (no)
TW (1) TW204342B (no)
ZA (1) ZA926013B (no)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2066623T3 (es) * 1992-03-13 1995-03-01 Bio Mega Boehringer Ingelheim Derivados sustituidos del acido pipecolinico como inhibidores de la vih-proteasa.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
KR100238346B1 (ko) * 1993-04-07 2000-03-02 오쓰까 아끼히꼬 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
HUT77318A (hu) * 1994-09-30 1998-03-30 Novartis Ag. 1-Acil-4-/(alifás amino)-piperidin/-származékok, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
HU226562B1 (en) * 1995-02-22 2009-04-28 Novartis Ag 1-aryl-2-acylamino-ethane compounds as neurokinin, especially neurokinin-1 antagonists, and medicaments containing the said compounds.
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
ATE199552T1 (de) 1995-07-07 2001-03-15 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
US6288225B1 (en) 1996-05-09 2001-09-11 Pfizer Inc Substituted benzolactam compounds as substance P antagonists
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
EP0873117A4 (en) * 1995-11-13 1999-02-24 Smithkline Beecham Corp HEMOREGULATORY CONNECTIONS
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
SI0892793T1 (en) * 1996-04-12 2003-10-31 Janssen Pharmaceutica N.V. Substituted tetracyclic tetrahydrofuran derivatives
WO1997045119A1 (en) * 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
EP0927192B1 (de) * 1996-09-10 2004-05-12 Boehringer Ingelheim Pharma GmbH & Co.KG Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1998024445A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
JP2001524960A (ja) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド 摂食障害を治療するためのnk−1受容体拮抗薬の使用
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
US6319920B1 (en) 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
AU5624599A (en) * 1998-08-25 2000-03-14 Lothar Farber Pharmaceutical uses
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
TR200103332T2 (tr) * 1999-05-21 2002-04-22 Pfizer Products Inc. 1-Triflorometil-4-hidroksi-7-piperidinil-aminometilkroman türevleri.
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
RU2309953C2 (ru) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
US7235531B2 (en) 1999-12-21 2007-06-26 Takeda Pharmaceutical Company Tachykinin-like polypeptides and use thereof
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
MXPA03000708A (es) 2000-07-26 2003-06-04 Smithkline Beecham Plc Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana.
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
UA75392C2 (en) 2001-02-23 2006-04-17 Merck & Co Inc N-substituted non-aryl heterocyclic antagonists nmda/nr2b
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
DE60224221T2 (de) * 2001-12-03 2008-12-11 F. Hoffmann-La Roche Ag Aminotetralinderivate, antagonisten von muscarinrezeptoren
JP4508650B2 (ja) * 2002-01-29 2010-07-21 グラクソ グループ リミテッド アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物
EP1470125A1 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine derivatives
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TWI283241B (en) * 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP2004285038A (ja) * 2002-05-31 2004-10-14 Takeda Chem Ind Ltd ピペリジン誘導体、その製造法および用途
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
EP1581517B1 (en) 2002-12-23 2007-02-21 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
DE60322110D1 (de) 2002-12-23 2008-08-21 Janssen Pharmaceutica Nv Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
JO2485B1 (en) 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
CN1886375A (zh) * 2003-11-28 2006-12-27 田边制药株式会社 哌啶化合物及其制法
MY142362A (en) 2004-01-29 2010-11-30 Otsuka Pharma Co Ltd Pharmaceutical composition for promoting angiogenesis
US7232831B2 (en) * 2004-03-22 2007-06-19 Mediquest Therapeutics, Inc. Tetrahydro-β-carboline compounds and use thereof
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
MX2007011079A (es) 2005-03-08 2007-10-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-[4-4]-nonano como antagonistas de la neurocinina (nk1).
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0607532D0 (en) * 2006-04-13 2006-05-24 Novartis Ag Organic compounds
JP5042311B2 (ja) * 2006-07-20 2012-10-03 ノバルティス アーゲー Cetp阻害剤としてのアミノピペリジン誘導体
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
CN102264701A (zh) * 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮脲
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2022155294A1 (en) * 2021-01-14 2022-07-21 Alexion Pharmaceuticals, Inc. Macrocycle complement factor b inhibitors
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5145967A (en) * 1989-04-20 1992-09-08 Anaquest, Inc. Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5126455A (en) * 1989-12-13 1992-06-30 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
ES2093099T3 (es) * 1990-05-31 1996-12-16 Pfizer Preparacion de piperidinas sustituidas.
ES2063507T3 (es) * 1990-06-01 1995-01-01 Pfizer 3-amino-2-aril-quinuclidinas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
DK0550635T3 (da) * 1990-09-28 1995-09-04 Pfizer Cykliske forbindelser med kondeserede ringe, som er analoger til nitrogenholdige ikke-aromatiske het erocykliske forbindelser

Also Published As

Publication number Publication date
SA94140632A (ar) 2005-12-03
KR930004297A (ko) 1993-03-22
AU660180B2 (en) 1995-06-15
AU2096592A (en) 1993-03-04
CA2075684C (en) 2003-01-07
EP0532456A1 (de) 1993-03-17
ES2070617T3 (es) 1995-06-01
RU2114829C1 (ru) 1998-07-10
FI923575A0 (fi) 1992-08-10
ATE120456T1 (de) 1995-04-15
HU9202615D0 (en) 1992-10-28
KR100261367B1 (ko) 2000-07-01
ZA926013B (en) 1993-03-31
PH29963A (en) 1996-09-25
MY110227A (en) 1998-03-31
HUT67088A (en) 1995-01-30
US5541195A (en) 1996-07-30
DK0532456T3 (da) 1995-06-12
JPH07196649A (ja) 1995-08-01
NO303448B1 (no) 1998-07-13
EP0532456B1 (de) 1995-03-29
IL102769A (en) 1999-01-26
US5310743A (en) 1994-05-10
CA2075684A1 (en) 1993-02-13
US5646144A (en) 1997-07-08
MX9204627A (es) 1993-04-01
JP3118090B2 (ja) 2000-12-18
NO973117L (no) 1993-02-15
NO923123D0 (no) 1992-08-11
DE59201771D1 (de) 1995-05-04
FI104631B (fi) 2000-03-15
NO923123L (no) 1993-02-15
IL118750A0 (en) 1996-10-16
HU221305B1 (en) 2002-09-28
FI923575A (fi) 1993-02-13
GR3015954T3 (en) 1995-07-31
IL102769A0 (en) 1993-01-31
TW204342B (no) 1993-04-21
NZ243888A (en) 1996-03-26

Similar Documents

Publication Publication Date Title
NO923123D0 (no) 1-acylpiperidinforbindelser
DK0463560T3 (da) Nye antiepileptiske midler
CA2044746A1 (en) Polypeptide compound and a process for preparation thereof
NZ332608A (en) alkyl 17-alpha-dichloroacetoxy-11- beta-hydroxy-androsta-1,4-diene-3-one-17-beta-carboxylates and medicaments
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
DE69400506D1 (de) Triterpenderivate und diese enthaltende Endothelinrezeptor Antagonisten
ATE38150T1 (de) Oximaether von alkylaminoalkoholen als heilmittelverbindungen und verfahren zu ihrer herstellung.
AU571841B2 (en) Carbacyclin pharmaceutical preparations
DE69426908D1 (de) Derivate der Phosphonsäure, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
ES8702379A1 (es) Un procedimiento para la produccion de 1h-tetrazol-5-carboxamidas-n-sustituidas.
ES8607972A1 (es) Procedimiento para la obtencion de compuestos heterociclicos penemicos
ES435361A1 (es) Un metodo para la preparacion de nuevos esteres alcohilicosde aminoacidos.
ATE92461T1 (de) Gegen die zerebrale insuffizienz wirksame verbindungen.
RU2053228C1 (ru) Производные пептидов, способ их получения, фармацевтическая композиция, ингибирующая эластазу человеческих лейкоцитов
TNSN98138A1 (fr) Nouveaux derives benzamides stimulants de la motricite gastrointestinale haute et basse
KR890003678A (ko) 부정맥 치료제
TH29704B (th) ไพราโซโลไพริมิดิน